Bioprocess and analytics priorities for the tissue engineered product and cell therapy fields
Cell & Gene Therapy Insights 2021; 7(4), 465–470
Published: 13 May 2021
Julie Allickson, PhD
Julie Allickson, PhD is Chief Manufacturing Development Center Officer at Wake Forest Institute for Regenerative Medicine. She heads the clinical translation team streamlining development to create a robust pipeline of products in development and early phase clinical trials including cellular therapy, genetically engineered cellular therapy, tissue engineered organs and tissues, biomaterials and devices. Prior to the Institute, she was the Vice President of Research and Development and Laboratory Operations for Cryo-Cell International Inc. Dr. Allickson has 30 years of experience in clinical translation of cellular therapies and regenerative medicine products including regulatory affairs, business management and board directorship experience. Other experience as an executive officer of a publicly traded company building services for cellular banking including licensure of technology.
Dr. Allickson was part of the team to perform the first Bone Marrow Transplant at the University of Miami in 1990’s and at Miami Children’s Hospital Bone Marrow Transplant Program. She has a Doctorate in Health Sciences- Clinical Immunology along with a Master’s Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy. She is on the Board of Directors for AABB Board, Regenerative Medicine Outcomes Foundation as a scientific advisor and Scientific Advisory Board for Alliance for Cell Therapy Now. She is an Associate Editor for Journal of Translational Medicine, on the Editorial board of CELLR4, Vice Chair for Cord Blood Association Quality Committee, Technical Advisory Board for Tissue Engineered Products under ICCBBA, grant reviewer for state funded initiatives such as CIRM and serves on the ISCT Commercialization Committee.